# Recurrent hyponatremia due to syndrome of inappropriate antidiuresis after traumatic brain injury: two case reports

**Authors:** Iulia Petria, Rita Indirli, Beatrice Mantovani, Valeria Lanzi, Giovanna Mantovani, Emanuele Ferrante

PMC · DOI: 10.3389/fendo.2025.1536247 · Frontiers in Endocrinology · 2025-03-06

## TL;DR

This paper reports two cases of recurring low sodium levels due to a condition called SIAD after traumatic brain injury, emphasizing the need for long-term monitoring.

## Contribution

The paper adds to the limited literature on chronic and recurrent SIAD following traumatic brain injury through detailed case reports.

## Key findings

- Two patients with traumatic brain injury developed recurrent hyponatremia due to SIAD despite treatment.
- Long-term management with tolvaptan helped maintain normal sodium levels in both cases.
- The cases highlight the importance of ongoing monitoring for electrolyte imbalances after head injury.

## Abstract

Transient hyponatremia due to syndrome of inappropriate antidiuresis (SIAD) is a frequent (20-50%) complication of traumatic brain injury (TBI), but it rarely persists or recurs. There are only few published reports of patients suffering from non-transient hyponatremia due to chronic SIAD after TBI. We report two more cases with this condition.

A 36-year-old woman suffering from major depression and treated with olanzapine reported severe TBI after a severe fall. Following head injury, she developed severe hyponatremia, which was managed with fluid restriction and salt supplementation. Upon hospital discharge, 7 months after trauma, mild hyponatremia was still reported (Na 134 mmol/L), which dropped to severe hyponatremia in a week despite continuation of treatment, and spontaneously returned to normal. Two months later, the patient presented one more episode of moderate hyponatremia without clear triggering events. Pituitary hormones were normal and urinary sodium and urinary and plasma osmolality supported the diagnosis of SIAD. Therefore, tolvaptan 7.5 mg daily was started, with sustained normalization of sodium levels. When olanzapine was stopped, discontinuation of tolvaptan was attempted. However, serum sodium dropped again and tolvaptan had to be resumed, with natremia remaining within normal range at follow-up. Consistently, olanzapine-related hyponatremia could be ruled out and post-traumatic SIAD confirmed.

A 37-year-old man experienced TBI with diffuse axonal injury falling during a mountain trip. Over the following year, he presented two episodes of tonic-clonic seizures accompanied by the biochemical finding of moderate-severe hyponatremia. Hyponatremia resolved following hypertonic (3% NaCl) saline infusion, and valproate treatment was started after the second episode. In the following outpatient visits, a progressive decrease of serum sodium from 141 mmol/L to 132 mmol/L was observed, with other tests consistent with SIAD. Therefore, considering the high risk of recurrent seizures as well as the concomitant treatment with valproate, tolvaptan 7.5 mg every other day was started and normal sodium levels have been maintained since then.

We report two cases of recurrent SIAD following TBI, with multiple hyponatremic episodes after initial presentation. This highlights the importance of long-term follow-up of electrolyte abnormalities after head injury.

## Linked entities

- **Chemicals:** olanzapine (PubChem CID 135398745), NaCl (PubChem CID 5234), valproate (PubChem CID 3549980), tolvaptan (PubChem CID 216237)
- **Diseases:** major depression (MONDO:0002009), traumatic brain injury (MONDO:0858950)

## Full-text entities

- **Diseases:** TBI (MESH:D000070642), Hyponatremia (MESH:D007010), head injury (MESH:D006259), electrolyte abnormalities (MESH:D014883), trauma (MESH:D014947), seizures (MESH:D012640), diffuse axonal injury (MESH:D020833), major depression (MESH:D003865), SIAD (MESH:C564491)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11922699/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11922699/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11922699/full.md

---
Source: https://tomesphere.com/paper/PMC11922699